# EDGAR Filing Document

**Accession Number:** 0001873835
**File Stem:** 0001493152-23-000915
**Filing Date:** 2023-1
**Character Count:** 2330
**Document Hash:** b6b5d737c4f236aa47d0218b3d1ddf99
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-000915.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0001493152-23-000915

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immix Biopharma, Inc.
- **CENTRAL INDEX KEY:** 0001873835
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 454869378
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 11400 WEST OLYMPIC BLVD.
- **STREET 2:** SUITE 200
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064
- **BUSINESS PHONE:** (888) 958-1084

**MAIL ADDRESS:**
- **STREET 1:** 10573 W. PICO BLVD.
- **STREET 2:** #58
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90064

**Immix Biopharma, Inc.**

11400 West Olympic Blvd., Suite 200

Los Angeles, CA 90064

January 9, 2023

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Lauren Hamill

---

| | |
|:---|:---|
| Re: | Immix Biopharma, Inc. |
|  | Registration Statement on Form S-3 |
|  | File No. 333-269100 |
|  | Filed January 3, 2023 |

---

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), Immix Biopharma, Inc. (the "Company") respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, January 11, 2023, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| IMMIX BIOPHARMA, INC. | IMMIX BIOPHARMA, INC. |
| By: | */s/ Ilya Rachman* |
| Name: | Ilya Rachman |
| Title: | CEO |

---

cc: Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP